Combining TP53 mutation and isoform has the potential to improve clinical practice

Sankalita Ray Das; Brett Delahunt; Annette Lasham; Kunyu Li; Deborah Wright; Cristin Print; Tania Slatter; Antony Braithwaite; Sunali Mehta

doi:10.1016/j.pathol.2024.02.003

Combining TP53 mutation and isoform has the potential to improve clinical practice

Pathology. 2024 Mar 19:S0031-3025(24)00087-4. doi: 10.1016/j.pathol.2024.02.003. Online ahead of print.

Authors

Sankalita Ray Das¹, Brett Delahunt², Annette Lasham³, Kunyu Li⁴, Deborah Wright⁵, Cristin Print³, Tania Slatter⁴, Antony Braithwaite⁴, Sunali Mehta⁶

Affiliations

¹ Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
² Pathology and Molecular Medicine, University of Otago, Wellington, New Zealand.
³ Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; Maurice Wilkins Centre for Biodiscovery, University of Auckland, Auckland, New Zealand; Te Aka Mātauranga Matepukupuku (Centre for Cancer Research), University of Auckland, Auckland, New Zealand.
⁴ Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand; Maurice Wilkins Centre for Biodiscovery, University of Auckland, Auckland, New Zealand.
⁵ Department of Surgical Sciences, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
⁶ Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand; Maurice Wilkins Centre for Biodiscovery, University of Auckland, Auckland, New Zealand. Electronic address: sunali.mehta@otago.ac.nz.

PMID: 38594116
DOI: 10.1016/j.pathol.2024.02.003

Abstract

The clinical importance of assessing and combining data on TP53 mutations and isoforms is discussed in this article. It gives a succinct overview of the structural makeup and key biological roles of the isoforms. It then provides a comprehensive summary of the roles that p53 isoforms play in cancer development, therapy response and resistance. The review provides a summary of studies demonstrating the role of p53 isoforms as potential prognostic indicators. It further provides evidence on how the presence of TP53 mutations may affect one or more of these activities and the association of p53 isoforms with clinicopathological data in various tumour types. The review gives insight into the present diagnostic hurdles for identifying TP53 isoforms and makes recommendations to improve their evaluation. In conclusion, this review offers suggestions for enhancing the identification and integration of TP53 isoforms in conjunction with mutation data within the clinical context.

Keywords: TP53 isoforms; clinical outcome; p53; preclinical.

Publication types

Review